Talk:Donanemab

Untitled
Process to harvest Donanemab

Donanemab was harvested from a biological origin. To produce the antibody to create donanedab, mice were injected with a specific antigen, a non-self cell, which induces an immune response. White blood cells are produced to destroy the antigen. B cells, which are a type of white blood cell, produce antibodies to bind and destroy the antigen. Antibodies produced are then harvested from the mouse to be fused with cancer B cells. This hybrid cell produces monoclonal antibodies used as the drug donanemab, that has the function of a B cell but long life of a Myeloma (Lowe, 2021).

Wiki Education Foundation-supported course assignment
This article is or was the subject of a Wiki Education Foundation-supported course assignment.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 16:44, 18 January 2022 (UTC)

A piece by BBC News which may help in expanding the article
The article is: https://www.bbc.com/news/health-66221116

It is shown to slow down Alzheimers substantially. 46.230.130.163 (talk) 14:24, 17 July 2023 (UTC)

Development
This entire section should be deleted. The production of humanized monoclonal antibodies in mice is long-established technology and describing it in laborious detail is not appropriate for an article about a specific drug generated with that technology. It is sufficient to say that donanemab is a humanized monoclonal antibody against amyloid beta protein. It doesn't matter how it was made. BostonBestEats (talk) 03:19, 12 June 2024 (UTC)